2021-08-24-上交所-寿仙谷2021年半年度报告_164页_2mb

Summary of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. 2021 Half-Year Report

1. Company Introduction

• Focus: Cultivation, processing, and sales of Lingzhi, stone斛 (铁皮石斛), and Xihonghua (西红花) herbs.
• Business Model: Combination of direct sales and distribution channels.
• Core Products: Lingzhi spore powder, stone斛 products, and health supplements.
• Position: National-level high-tech enterprise in the pharmaceutical industry.

2. Key Business Information

• Financial Highlights:
  • Revenue: RMB 317.49 million (up 34.40% YoY).
  • Net profit: RMB 54.99 million (up 29.86% YoY).
  • Basic earnings per share (EPS): RMB 0.37 (up 27.59% YoY).
• Gross Profit Margin: High, averaging around 84% in recent years.
• Industry Position: Leader in the field of cultivated Lingzhi and stone斛, with strong brand recognition.

3. Core Competitiveness

• Full Industrial Chain: Covers breeding, standardized planting, deep processing, and sales.
• Breeding Advantage: Developed proprietary varieties like "Shenshan No.1 Lingzhi" and "Shenshan No.3 Dendrobium."
• Quality Control: Adherence to organic and GMP standards in production.
• Innovation: Strong R&D capabilities, hosting multiple national and local standard-setting projects.

4. Risk Management

• Main Risks: Natural disasters, price fluctuations, raw material quality issues, policy changes, and liquidity risk.

This summary highlights the company's strong market position, financial performance, and future growth potential based on the 2021 half-year report. For detailed financial data and operational specifics, refer to the full report.